

# Everett E Vokes

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6532947/publications.pdf>

Version: 2024-02-01

220  
papers

37,797  
citations

25034

57  
h-index

2953

189  
g-index

222  
all docs

222  
docs citations

222  
times ranked

28833  
citing authors

#	ARTICLE	IF	CITATIONS
1	Nivolumab versus Docetaxel in Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 1627-1639.	27.0	7,973
2	Nivolumab versus Docetaxel in Advanced Squamous-Cell Nonâ€“Small-Cell Lung Cancer. New England Journal of Medicine, 2015, 373, 123-135.	27.0	7,261
3	Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. New England Journal of Medicine, 2016, 375, 1856-1867.	27.0	3,845
4	Head and Neck Cancer. New England Journal of Medicine, 1993, 328, 184-194.	27.0	1,690
5	Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Nonâ€“Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens. Journal of Clinical Oncology, 2000, 18, 2354-2362.	1.6	1,297
6	Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. New England Journal of Medicine, 2022, 386, 1973-1985.	27.0	871
7	Predictors of Competing Mortality in Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2010, 28, 15-20.	1.6	765
8	Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Nonâ€“Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and) Tj ETQq0 0 QngBT /Overclock 10 T	1.6	765
9	Lung cancer. Lancet, The, 2000, 355, 479-485.	13.7	606
10	Nivolumab vs investigatorâ€™s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression. Oral Oncology, 2018, 81, 45-51.	1.5	589
11	Phase II Trial of ZD1839 in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2003, 21, 1980-1987.	1.6	568
12	The performance status scale for head and neck cancer patients and the functional assessment of cancer therapy-head and neck scale: A study of utility and validity. Cancer, 1996, 77, 2294-2301.	4.1	533
13	Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas. Clinical Cancer Research, 2015, 21, 632-641.	7.0	525
14	Phase III Randomized Trial of Induction Chemotherapy in Patients With N2 or N3 Locally Advanced Head and Neck Cancer. Journal of Clinical Oncology, 2014, 32, 2735-2743.	1.6	458
15	Induction Chemotherapy Followed by Chemoradiotherapy Compared With Chemoradiotherapy Alone for Regionally Advanced Unresectable Stage III Nonâ€“Small-Cell Lung Cancer: Cancer and Leukemia Group B. Journal of Clinical Oncology, 2007, 25, 1698-1704.	1.6	437
16	Phase II Multicenter Study of the Epidermal Growth Factor Receptor Antibody Cetuximab and Cisplatin for Recurrent and Refractory Squamous Cell Carcinoma of the Head and Neck. Journal of Clinical Oncology, 2005, 23, 5578-5587.	1.6	382
17	Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Nonâ€“Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431. Journal of Clinical Oncology, 2002, 20, 4191-4198.	1.6	365
18	PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Nonâ€“Small-Cell Lung Cancer. Journal of Clinical Oncology, 2016, 34, 953-962.	1.6	365

#	ARTICLE	IF	CITATIONS
19	Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 723-733.	1.6	329
20	Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 1104-1115.	10.7	325
21	Integrative Analysis of Head and Neck Cancer Identifies Two Biologically Distinct HPV and Three Non-HPV Subtypes. <i>Clinical Cancer Research</i> , 2015, 21, 870-881.	7.0	303
22	The MET Receptor Tyrosine Kinase Is a Potential Novel Therapeutic Target for Head and Neck Squamous Cell Carcinoma. <i>Cancer Research</i> , 2009, 69, 3021-3031.	0.9	236
23	Quality of Life and Performance in Advanced Head and Neck Cancer Patients on Concomitant Chemoradiotherapy: A Prospective Examination. <i>Journal of Clinical Oncology</i> , 1999, 17, 1020-1020.	1.6	223
24	Weekly Carboplatin and Paclitaxel Followed by Concomitant Paclitaxel, Fluorouracil, and Hydroxyurea Chemoradiotherapy: Curative and Organ-Preserving Therapy for Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2003, 21, 320-326.	1.6	216
25	The Expanding Role of Systemic Therapy in Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 1743-1752.	1.6	199
26	The chemoradiation paradigm in head and neck cancer. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 156-171.	4.3	194
27	Concomitant Chemoradiotherapy as Primary Therapy for Locoregionally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2000, 18, 1652-1661.	1.6	190
28	Swallowing dysfunction—preventative and rehabilitation strategies in patients with head-and-neck cancers treated with surgery, radiotherapy, and chemotherapy: A critical review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003, 57, 1219-1230.	0.8	190
29	Randomized Phase II Study of Pemetrexed, Carboplatin, and Thoracic Radiation With or Without Cetuximab in Patients With Locally Advanced Unresectable Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 30407. <i>Journal of Clinical Oncology</i> , 2011, 29, 3120-3125.	1.6	186
30	The Potential of Combined Immunotherapy and Antiangiogenesis for the Synergistic Treatment of Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2017, 12, 194-207.	1.1	186
31	The Role of Cervical Lymphadenectomy After Aggressive Concomitant Chemoradiotherapy. <i>JAMA Otolaryngology</i> , 2000, 126, 950.	1.2	176
32	Randomized Phase III Intergroup Trial of Etoposide and Cisplatin With or Without Paclitaxel and Granulocyte Colony-Stimulating Factor in Patients With Extensive-Stage Small-Cell Lung Cancer: Cancer and Leukemia Group B Trial 9732. <i>Journal of Clinical Oncology</i> , 2005, 23, 3752-3759.	1.6	176
33	Randomized Phase II Trial of Induction Chemotherapy Followed by Concurrent Chemotherapy and Dose-Escalated Thoracic Conformal Radiotherapy (74 Gy) in Stage III Non-Small-Cell Lung Cancer: CALGB 30105. <i>Journal of Clinical Oncology</i> , 2008, 26, 2457-2463.	1.6	169
34	Competing Causes of Death and Second Primary Tumors in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Chemoradiotherapy. <i>Clinical Cancer Research</i> , 2004, 10, 1956-1962.	7.0	159
35	HPV-Associated Head and Neck Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 107, djv344.	6.3	153
36	Concomitant Infusional Paclitaxel and Fluorouracil, Oral Hydroxyurea, and Hyperfractionated Radiation for Locally Advanced Squamous Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2001, 19, 1961-1969.	1.6	145

#	ARTICLE	IF	CITATIONS
37	Site of disease and treatment protocol as correlates of swallowing function in patients with head and neck cancer treated with chemoradiation. <i>Head and Neck</i> , 2006, 28, 64-73.	2.0	138
38	Chemoradiotherapy and Gefitinib in Stage III Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor and KRAS Mutation Analysis: Cancer and Leukemia Group B (CALEB) 30106, a CALGB-Stratified Phase II Trial. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1382-1390.	1.1	138
39	Is Patient Travel Distance Associated With Survival on Phase II Clinical Trials in Oncology?. <i>Journal of the National Cancer Institute</i> , 2003, 95, 1370-1375.	6.3	133
40	Neck dissection in the combined-modality therapy of patients with locoregionally advanced head and neck cancer. <i>Head and Neck</i> , 2004, 26, 447-455.	2.0	130
41	Lung cancer—a fractal viewpoint. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 664-675.	27.6	129
42	Activity of Docetaxel in Platinum-Treated Non-Small-Cell Lung Cancer: Results of a Phase II Multicenter Trial. <i>Journal of Clinical Oncology</i> , 2000, 18, 131-131.	1.6	128
43	Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study—CALGB 30504 (Alliance). <i>Journal of Clinical Oncology</i> , 2015, 33, 1660-1665.	1.6	126
44	Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use. <i>Clinical Cancer Research</i> , 2019, 25, 5221-5230.	7.0	115
45	Bcl-xL and Bcl-2 expression in squamous cell carcinoma of the head and neck. , 1999, 85, 164-170.		108
46	A Phase II Study of Lapatinib in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2012, 18, 2336-2343.	7.0	104
47	ALCHEMIST Trials: A Golden Opportunity to Transform Outcomes in Early-Stage Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2015, 21, 5439-5444.	7.0	104
48	Aspiration in Chemoradiated Patients With Head and Neck Cancer. <i>JAMA Otolaryngology</i> , 2007, 133, 1289.	1.2	91
49	ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016. <i>ESMO Open</i> , 2016, 1, e000097.	4.5	82
50	Chemoradiotherapy for Locally Advanced Head and Neck Cancer. <i>Journal of Clinical Oncology</i> , 2007, 25, 4118-4126.	1.6	79
51	Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. <i>Head and Neck</i> , 1989, 11, 437-442.	2.0	77
52	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, LBA109-LBA109.	1.6	74
53	Locally Advanced Non-small Cell Lung Cancer: The Past, Present, and Future. <i>Journal of Thoracic Oncology</i> , 2008, 3, 917-928.	1.1	71
54	New Radiotherapy and Chemoradiotherapy Approaches for Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2013, 31, 1029-1038.	1.6	70

#	ARTICLE	IF	CITATIONS
55	Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. <i>Journal of Clinical Oncology</i> , 2017, 35, 2885-2892.	1.6	68
56	Biomarker-driven therapies for previously treated squamous non-small-cell lung cancer (Lung-MAP). <i>Journal of Clinical Oncology</i> , 2017, 35, 2893-2901.	10.7	68
57	Phase I Trial of Erlotinib-Based Multimodality Therapy for Inoperable Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 1003-1011.	1.1	64
58	Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial. <i>Cancer</i> , 2019, 125, 3208-3218.	4.1	64
59	Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). <i>Journal of Clinical Oncology</i> , 2017, 35, 2184-2192.	1.6	63
60	Optimizing Treatment De-Escalation in Head and Neck Cancer: Current and Future Perspectives. <i>Oncologist</i> , 2021, 26, 40-48.	3.7	57
61	Efficacy and safety of treating T4 oral cavity tumors with primary chemoradiotherapy. <i>Head and Neck</i> , 2009, 31, 1013-1021.	2.0	53
62	CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. <i>Scientific Reports</i> , 2021, 11, 20059.	3.3	53
63	PROCLAIM: A Phase III Study of Pemetrexed, Cisplatin, and Radiation Therapy Followed by Consolidation Pemetrexed Versus Etoposide, Cisplatin, and Radiation Therapy Followed by Consolidation Cytotoxic Chemotherapy of Choice in Locally Advanced Stage III Non-Small-Cell Lung Cancer of Other than Predominantly Squamous Cell Histology. <i>Clinical Lung Cancer</i> , 2009, 10, 193-198.	2.6	50
64	A Phase 1 Trial of Concurrent or Sequential Ipilimumab, Nivolumab, and Stereotactic Body Radiotherapy in Patients With Stage IV NSCLC Study. <i>Journal of Thoracic Oncology</i> , 2022, 17, 130-140.	1.1	49
65	Chemotherapy in the management of squamous-cell carcinoma of the head and neck. <i>Lancet Oncology</i> , 2001, 2, 261-269.	10.7	48
66	Intensive Concurrent Chemoradiotherapy for Head and Neck Cancer with 5-Fluorouracil and Hydroxyurea-Based Regimens: Reversing a Pattern of Failure. <i>Oncologist</i> , 2003, 8, 350-360.	3.7	45
67	Twice-daily reirradiation for recurrent and second primary head-and-neck cancer with gemcitabine, paclitaxel, and 5-fluorouracil chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2005, 61, 1096-1106.	0.8	44
68	Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor. <i>Cancer</i> , 2018, 124, 2174-2183.	4.1	44
69	A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer. <i>Cancer</i> , 1989, 63, 30-36.	4.1	42
70	Induction Chemotherapy for Head and Neck Cancer: Recent Data. <i>Oncologist</i> , 2010, 15, 3-7.	3.7	42
71	Definitive chemoradiation for locally-advanced oral cavity cancer: A 20-year experience. <i>Oral Oncology</i> , 2018, 80, 16-22.	1.5	42
72	Adjuvant chemoradiotherapy for locoregionally advanced and high-risk salivary gland malignancies. <i>Head &amp; Neck Oncology</i> , 2011, 3, 31.	2.3	41

#	ARTICLE	IF	CITATIONS
73	Treatment Outcomes of Different Prognostic Groups of Patients on Cancer and Leukemia Group B Trial 39801: Induction Chemotherapy Followed by Chemoradiotherapy Compared with Chemoradiotherapy Alone for Unresectable Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 1117-1125.	1.1	40
74	Ex Vivo Antibody-Dependent Cellular Cytotoxicity Inducibility Predicts Efficacy of Cetuximab. <i>Cancer Immunology Research</i> , 2015, 3, 567-574.	3.4	38
75	Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 177-185.	0.8	35
76	Radiotherapy and immunotherapy converge on elimination of tumor-promoting erythroid progenitor cells through adaptive immunity. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	35
77	Exosomal miRNAs species in the blood of small cell and non-small cell lung cancer patients. <i>Oncotarget</i> , 2018, 9, 19793-19806.	1.8	34
78	A randomized study comparing two regimens of neoadjuvant and adjuvant chemotherapy in multimodal therapy for locally advanced head and neck cancer. <i>Cancer</i> , 1990, 66, 206-213.	4.1	33
79	Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. <i>Journal of Geriatric Oncology</i> , 2013, 4, 327-333.	1.0	33
80	35-year-old patient with chronic myelogenous leukemia developing systemic lupus erythematosus after $\alpha$ -interferon therapy. <i>American Journal of Hematology</i> , 1992, 41, 141-141.	4.1	31
81	Optimal Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2005, 23, 5853-5855.	1.6	31
82	Induction Paclitaxel/Carboplatin Followed by Concurrent Chemoradiation Therapy for Unresectable Stage III Non-Small-Cell Lung Cancer: A Limited-Access Study (CALGB 9534). <i>Clinical Lung Cancer</i> , 2005, 7, 47-53.	2.6	31
83	Identification of neoantigen-specific T cells and their targets: implications for immunotherapy of head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2019, 8, e1568813.	4.6	31
84	Nivolumab (nivo) in patients (pts) with advanced (adv) NSCLC and central nervous system (CNS) metastases (mets).. <i>Journal of Clinical Oncology</i> , 2016, 34, 9038-9038.	1.6	31
85	How I do it: Head and neck and plastic surgery: Surgical management of the head and neck cancer patient following concomitant multimodality therapy. <i>Laryngoscope</i> , 1995, 105, 97-101.	2.0	30
86	Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced biliary carcinoma. <i>Investigational New Drugs</i> , 1999, 17, 97-101.	2.6	30
87	Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 5781-5792.	7.0	30
88	Final Results of a Randomized Phase 2 Trial Investigating the Addition of Cetuximab to Induction Chemotherapy and Accelerated or Hyperfractionated Chemoradiation for Locoregionally Advanced Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 21-29.	0.8	29
89	Randomized Study of Maintenance Pemetrexed Versus Observation for Treatment of Malignant Pleural Mesothelioma: CALGB 30901. <i>Clinical Lung Cancer</i> , 2020, 21, 553-561.e1.	2.6	29
90	Concurrent Chemoradiotherapy for Unresectable Stage III Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 5045s-5050s.	7.0	28

#	ARTICLE	IF	CITATIONS
91	Time-dose relationship for local tumor control following alternate week concomitant radiation and chemotherapy of advanced head and neck cancer. International Journal of Radiation Oncology Biology Physics, 1994, 29, 153-162.	0.8	27
92	Evaluation of neuropathy in patients on suramin treatment. Muscle and Nerve, 1997, 20, 83-91.	2.2	27
93	Radiation Therapy With Concomitant Hydroxyurea and Fluorouracil in Stage II and III Head and Neck Cancer. Journal of Clinical Oncology, 1999, 17, 638-638.	1.6	27
94	Race and competing mortality in advanced head and neck cancer. Oral Oncology, 2014, 50, 40-44.	1.5	27
95	Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study. Journal of Clinical Oncology, 2021, 39, 3633-3644.	1.6	27
96	A phase III study (CheckMate 017) of nivolumab (NIVO; anti-programmed death-1 [PD-1]) vs docetaxel (DOC) in previously treated advanced or metastatic squamous (SQ) cell non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2015, 33, 8009-8009.	1.6	27
97	Concurrent Chemotherapy and Intensity-Modulated Radiotherapy for Organ Preservation of Locoregionally Advanced Oral Cavity Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 356-361.	1.3	26
98	Rare occurrence of EGFRvIII deletion in head and neck squamous cell carcinoma. Oral Oncology, 2015, 51, 53-58.	1.5	26
99	Programmed Death-Ligand 1 Immunohistochemistry Assay Comparison Studies in NSCLC: Characterization of the 73-10 Assay. Journal of Thoracic Oncology, 2020, 15, 1306-1316.	1.1	26
100	Concomitant Chemoradiotherapy With Cisplatin, 5-Fluorouracil and Hydroxyurea in Poor-Prognosis Head and Neck Cancer. Laryngoscope, 1992, 102, 630-636.	2.0	25
101	Maximizing survival and minimizing toxicity. Nature Reviews Clinical Oncology, 2011, 8, 72-74.	27.6	25
102	Comprehensive genetic testing identifies targetable genomic alterations in most patients with non-small cell lung cancer, specifically adenocarcinoma, single institute investigation. Oncotarget, 2016, 7, 18876-18886.	1.8	25
103	A randomized validation study comparing embedded versus extracted FACT Head and Neck Symptom Index scores. Quality of Life Research, 2007, 16, 1615-1626.	3.1	24
104	A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer, 2020, 126, 2146-2152.	4.1	24
105	All-trans retinoic acid overcomes solid tumor radioresistance by inducing inflammatory macrophages. Science Immunology, 2021, 6, .	11.9	24
106	Therapeutic Options for Laryngeal Cancer. New England Journal of Medicine, 2003, 349, 2087-2089.	27.0	23
107	Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clinical Cancer Research, 2021, 27, 5510-5518.	7.0	23
108	Differences in Clinical Trial Patient Attributes and Outcomes According to Enrollment Setting. Journal of Clinical Oncology, 2010, 28, 215-221.	1.6	22



#	ARTICLE	IF	CITATIONS
109	Role of dental hardware in oral cavity squamous cell carcinoma in the low-risk nonsmoker nondrinker population. <i>Head and Neck</i> , 2018, 40, 784-792.	2.0	22
110	Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. <i>Cancer</i> , 1997, 79, 588-594.	4.1	21
111	Phase I Study of Concomitant Chemoradiotherapy with Paclitaxel, Fluorouracil, Gemcitabine, and Twice-Daily Radiation in Patients with Poor-Prognosis Cancer of the Head and Neck. <i>Clinical Cancer Research</i> , 2004, 10, 4922-4932.	7.0	21
112	Induction Chemotherapy: To Use or Not to Use? That Is the Question. <i>Seminars in Radiation Oncology</i> , 2009, 19, 11-16.	2.2	21
113	Characterization of the T-Cell Receptor Repertoire and Immune Microenvironment in Patients with Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck. <i>Clinical Cancer Research</i> , 2017, 23, 4897-4907.	7.0	21
114	A phase I trial of the oral platinum analogue JM216 with concomitant radiotherapy in advanced malignancies of the chest. <i>Investigational New Drugs</i> , 2001, 19, 303-310.	2.6	20
115	A phase II trial of 9-aminocaptothecin (9-AC) as a 120-h infusion in patients with non-small cell lung cancer. <i>Investigational New Drugs</i> , 2001, 19, 329-333.	2.6	20
116	Chemoradiotherapy for locoregionally advanced squamous cell carcinoma of the base of tongue. <i>Head and Neck</i> , 2010, 32, 1519-1527.	2.0	20
117	Nivolumab (Nivo) vs investigator's choice (IC) for platinum-refractory (PR) recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN; Checkmate 141): Outcomes in first-line (1L) R/m patients and updated safety and efficacy.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6019-6019.	1.6	20
118	Chemotherapy-related hemolytic-uremic syndrome after the treatment of head and neck cancer. A case report. <i>Cancer</i> , 1990, 66, 1914-1918.	4.1	19
119	A phase II study of piritrexim in combination with methotrexate in recurrent and metastatic head and neck cancer. <i>Cancer</i> , 1991, 67, 2253-2257.	4.1	19
120	A randomized phase II trial of the MET inhibitor tivantinib + cetuximab versus cetuximab alone in patients with recurrent/metastatic head and neck cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 6060-6060.	1.6	19
121	5-Fluorouracil With Oral Leucovorin and Hydroxyurea and Concomitant Radiotherapy for Stage III Non-Small Cell Lung Cancer. <i>Cancer</i> , 1990, 66, 437-442.	4.1	18
122	A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-amine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days. <i>Cancer Chemotherapy and Pharmacology</i> , 1999, 43, 385-388.	2.3	17
123	Locally advanced head and neck cancer. <i>Current Treatment Options in Oncology</i> , 2001, 2, 7-13.	3.0	17
124	Adjuvant and neoadjuvant treatments for NSCLC. <i>Lung Cancer</i> , 2002, 38, 29-35.	2.0	17
125	Concurrent chemoradiotherapy for head and neck cancer. <i>Seminars in Oncology</i> , 2004, 31, 786-793.	2.2	17
126	Novel EPHB4 Receptor Tyrosine Kinase Mutations and Kinomic Pathway Analysis in Lung Cancer. <i>Scientific Reports</i> , 2015, 5, 10641.	3.3	17



#	ARTICLE	IF	CITATIONS
127	Integrated Genomic Analysis Suggests <i>MLL3</i> Is a Novel Candidate Susceptibility Gene for Familial Nasopharyngeal Carcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2015, 24, 1222-1228.	2.5	17
128	Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1171-1182.	1.1	17
129	Targeted therapies for stage III non-small cell lung cancer: integration in the combined modality setting. <i>Lung Cancer</i> , 2003, 41, 115-121.	2.0	16
130	A Phase I Study of STEALTH® Cisplatin (SPI-77) and Vinorelbine in Patients with Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2000, 2, 128-132.	2.6	15
131	Non-Small-Cell Lung Cancer. <i>Chest</i> , 1994, 106, 659-661.	0.8	14
132	Clinical Studies in Non-small Cell Lung Cancer: The CALGB Experience. <i>Cancer Investigation</i> , 1998, 16, 72-79.	1.3	14
133	EGFR-directed treatments in SCCHN. <i>Lancet Oncology</i> , The, 2013, 14, 672-673.	10.7	14
134	A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. <i>Cancer</i> , 2019, 125, 382-390.	4.1	14
135	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. <i>PLoS ONE</i> , 2014, 9, e102112.	2.5	14
136	Performance and quality of life outcomes for T4 laryngeal cancer patients treated with induction chemotherapy followed by chemoradiotherapy. <i>Oral Oncology</i> , 2012, 48, 1025-1030.	1.5	13
137	AHNS Series “Do you know your guidelines? Principles of treatment for nasopharyngeal cancer: A review of the National Comprehensive Cancer Network guidelines. <i>Head and Neck</i> , 2017, 39, 201-205.	2.0	13
138	Management of Early Head and Neck Cancer in Elderly Patients. <i>Journal of Oncology Practice</i> , 2018, 14, 541-546.	2.5	13
139	Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2019, 14, 298-303.	1.1	13
140	Dose and Volume De-Escalation for Human Papillomavirus-Positive Oropharyngeal Cancer is Associated with Favorable Posttreatment Functional Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 662-671.	0.8	13
141	A phase I trial adding poly(ADP-ribose) polymerase inhibitor veliparib to induction carboplatin-paclitaxel in patients with head and neck squamous cell carcinoma: Alliance A091101. <i>Oral Oncology</i> , 2021, 114, 105171.	1.5	13
142	Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). <i>Journal of Clinical Oncology</i> , 2015, 33, LBA109-LBA109.	1.6	13
143	Crizotinib: ALK/Met inhibitor, oncolytic. <i>Drugs of the Future</i> , 2011, 36, 91.	0.1	13
144	The Impact of Staging by Positron-Emission Tomography on Overall Survival and Progression-Free Survival in Patients With Locally Advanced NSCLC. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1183-1188.	1.1	12

#	ARTICLE	IF	CITATIONS
145	A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab-resistant head and neck cancer: The MAESTRO study. <i>Cancer</i> , 2020, 126, 3237-3243.	4.1	12
146	Nivolumab (Nivo) vs investigator's choice (IC) in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Efficacy and safety in CheckMate 141 by prior cetuximab use. <i>Journal of Clinical Oncology</i> , 2017, 35, 6020-6020.	1.6	12
147	Concomitant Hydroxyurea, 5-Fluorouracil, and Radiation Therapy for Recurrent Head and Neck Cancer: Early Results. <i>Otolaryngology - Head and Neck Surgery</i> , 1988, 98, 295-298.	1.9	11
148	Phase II trial of aminocamptothecin (9-AC/DMA) in patients with advanced squamous cell head and neck cancer. <i>Investigational New Drugs</i> , 2000, 18, 261-263.	2.6	11
149	Double-blind, randomized crossover study of metoclopramide and batanopride for prevention of cisplatin-induced emesis. <i>Cancer Chemotherapy and Pharmacology</i> , 1991, 28, 226-227.	2.3	10
150	Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2001, 6, 25-27.	3.7	10
151	Phase I Study of Concomitant Chemoradiotherapy with Irinotecan, 5-FU., and Hydroxyurea for Patients with Advanced and/or Recurrent Head and Neck Cancer. <i>Cancer Journal (Sudbury, Mass )</i> , 2005, 11, 140-146.	2.0	10
152	A Phase I Trial of Docetaxel Based Induction and Concomitant Chemotherapy in Patients with Locally Advanced Head and Neck Cancer. <i>Cancer Investigation</i> , 2007, 25, 435-444.	1.3	10
153	Final overall survival (OS) results of the phase III PROCLAIM trial: Pemetrexed (Pem), cisplatin (Cis) or etoposide (Eto), Cis plus thoracic radiation therapy (TRT) followed by consolidation cytotoxic chemotherapy (CTX) in locally advanced nonsquamous non-small cell lung cancer (nsNSCLC). <i>Journal of Clinical Oncology</i> , 2015, 33, 7506-7506.	1.6	10
154	Risk and response adapted de-intensified treatment for HPV-associated oropharyngeal cancer: Optima paradigm expanded experience. <i>Oral Oncology</i> , 2021, 122, 105566.	1.5	10
155	Concomitant Chemoradiotherapy. <i>Journal of Clinical Oncology</i> , 2007, 25, 4031-4032.	1.6	9
156	Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. <i>Oncologist</i> , 2017, 22, 189-198.	3.7	9
157	Flow cytometry in hairy cell leukemia before and during interferon alfa-2b therapy. <i>Cancer</i> , 1987, 59, 1987-1991.	4.1	8
158	Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). <i>Journal of Thoracic Oncology</i> , 2016, 11, 361-369.	1.1	8
159	Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. <i>Lung Cancer</i> , 2021, 156, 68-71.	2.0	8
160	Continuous-infusion fluorodeoxyuridine with leucovorin and high-dose interferon: a phase II study in metastatic renal-cell cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1992, 31, 213-216.	2.3	7
161	Cooperative Group Portfolio in Locally Advanced Non-Small-Cell Lung Cancer: Are We Making Progress?. <i>Clinical Lung Cancer</i> , 2008, 9, 85-91.	2.6	7
162	Poly (ADP-ribose) polymerase inhibitor efficacy in head and neck cancer. <i>Oral Oncology</i> , 2014, 50, 825-831.	1.5	7

#	ARTICLE	IF	CITATIONS
163	Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. <i>Lung Cancer</i> , 2021, 159, 56-65.	2.0	7
164	A Phase 1b Study of Telisotuzumab Vedotin in Combination With Nivolumab in Patients With NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100262.	1.1	7
165	Radioresistant tumor cell lines derived from head and neck radiation failures. <i>Head and Neck</i> , 1989, 11, 343-348.	2.0	6
166	Treatment of head and neck and esophageal xenografts employing Alimta and concurrent ionizing radiation. <i>International Journal of Oncology</i> , 2001, 19, 833-5.	3.3	6
167	9-Aminocamptothecin (9-AC) given as a 120-hour continuous infusion in patients with advanced adenocarcinomas of the stomach and gastroesophageal junction: A phase II trial of the University of Chicago phase II consortium. <i>Investigational New Drugs</i> , 2004, 22, 323-327.	2.6	6
168	Induction chemotherapy and radiotherapy in locally advanced non-small cell lung cancer. <i>Hematology/Oncology Clinics of North America</i> , 2004, 18, 81-90.	2.2	6
169	Phase I Study of Induction Chemotherapy and Concomitant Chemoradiotherapy with Irinotecan, Carboplatin, and Paclitaxel for Stage III Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 59-67.	1.1	6
170	Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. <i>Lung Cancer</i> , 2015, 90, 281-287.	2.0	6
171	Similarity and difference in tumor-infiltrating lymphocytes in original tumor tissues and those of <i>in vitro</i> expanded populations in head and neck cancer. <i>Oncotarget</i> , 2018, 9, 3805-3814.	1.8	6
172	Expression and mutational analysis of c-CBL and its relationship to the MET receptor in head and neck squamous cell carcinoma. <i>Oncotarget</i> , 2017, 8, 18726-18734.	1.8	6
173	Peripheral blood mononuclear cell dihydropyrimidine dehydrogenase activity in volunteers with and without diabetes mellitus. <i>Cancer Chemotherapy and Pharmacology</i> , 1996, 37, 569-573.	2.3	5
174	Intensity-modulated radiation therapy in advanced head and neck patients treated with intensive chemoradiotherapy: preliminary experience and future directions. <i>International Journal of Oncology</i> , 2006, 28, 1141.	3.3	5
175	EGFR-based bioradiotherapy in SCCHN. <i>Lancet Oncology</i> , The, 2015, 16, 129-130.	10.7	5
176	Epidermal Growth Factor Receptor Blockade in Head and Neck Cancer: What Remains?. <i>Journal of Clinical Oncology</i> , 2019, 37, 2807-2814.	1.6	5
177	A phase I/II trial adding poly(ADP-ribose) polymerase (PARP) inhibitor veliparib to induction carboplatin-paclitaxel (Carbo-Tax) in patients with head and neck squamous cell carcinoma (HNSCC) Alliance A091101. <i>Journal of Clinical Oncology</i> , 2018, 36, 6031-6031.	1.6	5
178	Heuristic value-based framework for lung cancer decision-making. <i>Oncotarget</i> , 2018, 9, 29877-29891.	1.8	5
179	Prospective study evaluating dynamic changes of cell-free HPV DNA in locoregional viral-associated oropharyngeal cancer treated with induction chemotherapy and response-adaptive treatment. <i>BMC Cancer</i> , 2022, 22, 17.	2.6	5
180	Phase I study of escalating doses of mitoxantrone and paclitaxel with granulocyte-macrophage colony stimulating factor support. , 1996, 77, 2308-2312.		4

#	ARTICLE	IF	CITATIONS
181	A Phase I study of raltitrexed and paclitaxel given every 3 weeks to patients with solid tumors. Cancer, 1999, 86, 528-532.	4.1	4
182	Molecular Inhibition of mTOR with Temsirolimus (TORISELâ„¢, CCI-779) Is a Promising Strategy in Relapsed NHL: The University of Chicago Phase II Consortium.. Blood, 2006, 108, 2483-2483.	1.4	3
183	ALCHEMIST: a clinical trial platform to bring genomic discovery and molecularly targeted therapies to early-stage lung cancer.. Journal of Clinical Oncology, 2015, 33, TPS7583-TPS7583.	1.6	3
184	Molecular characterization of immune exclusion in small-cell lung cancer.. Journal of Clinical Oncology, 2016, 34, 8565-8565.	1.6	3
185	Development and Validation of a Decision Analytical Model for Posttreatment Surveillance for Patients With Oropharyngeal Carcinoma. JAMA Network Open, 2022, 5, e227240.	5.9	3
186	Phase ii trial of etoposide and doxorubicin in advanced head and neck cancer. Medical and Pediatric Oncology, 1990, 18, 487-490.	1.0	2
187	Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study. Cancer Chemotherapy and Pharmacology, 1993, 32, 347-352.	2.3	2
188	Phase I Study of Dose-Dense Alternating Doublets in Advanced Nonâ€”Small-Cell Lung Cancer. Clinical Lung Cancer, 2002, 3, 265-270.	2.6	2
189	Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. Lung Cancer, 2003, 42, 65-69.	2.0	2
190	O-307 A two-arm phase I study of OSI-774 in combination with chemoradiation for patients with unresectable, locally advanced non-small cell lung cancer. Lung Cancer, 2003, 41, S89.	2.0	2
191	The Cancer and Leukemia Group B Respiratory Committee. Clinical Cancer Research, 2006, 12, 3581s-3588s.	7.0	2
192	ALK and ROS1 rearrangement in NSCLC: rapidly evolving standards. Lancet Oncology, The, 2017, 18, 1555-1556.	10.7	2
193	Prolonging Life, but at What Price?. JAMA Otolaryngology - Head and Neck Surgery, 2019, 145, 1103.	2.2	2
194	Patterns of CD8+ T-cell infiltration and immune escape mechanisms in head and neck cancer.. Journal of Clinical Oncology, 2015, 33, 6078-6078.	1.6	2
195	Randomized phase 2 trial of cediranib alone or cediranib plus lenalidomide in iodine 131-refractory differentiated thyroid cancer (DTC): A University of Chicago Phase 2 Consortium trial.. Journal of Clinical Oncology, 2016, 34, 6013-6013.	1.6	2
196	A pooled analysis of concurrent chemoradiotherapy (CCRT) for patients with stage III non-small cell lung cancer (NSCLC) who participated in U.S. cooperative group trials: Comparing the outcomes of elderly to younger patients (pts).. Journal of Clinical Oncology, 2016, 34, 8508-8508.	1.6	2
197	A Phase II Trial of Oral Trimethylcolchicinic Acid in Patients with Hormone Refractory Prostate Cancer. Prostate Journal, 1999, 1, 195-202.	0.2	1
198	CI-980 in advanced melanoma and hormone refractory prostate cancer. Investigational New Drugs, 2000, 18, 187-191.	2.6	1

#	ARTICLE	IF	CITATIONS
199	Trends and perspectives in multimodality therapy of locoregionally advanced non-small cell lung cancer. Lung Cancer, 2001, 33, S85-S89.	2.0	1
200	Seeking improved outcome in the curative treatment of non-small-cell lung cancer. Lung Cancer, 2005, 50, S20-S22.	2.0	1
201	Palbociclib: a new partner for cetuximab?. Lancet Oncology, The, 2019, 20, 1195-1196.	10.7	1
202	Healthcare resource utilization and associated cost analysis of the PROCLAIM study in patients with stage III non-small-cell lung cancer. Current Medical Research and Opinion, 2019, 35, 1761-1767.	1.9	1
203	Adjuvant treatment for high-risk salivary gland malignancies and prognostic stratification based on a 20-year single institution experience. Health Science Reports, 2020, 3, e195.	1.5	1
204	Is This the Dawn of Precision Oncology in Head and Neck Cancer?. Journal of Clinical Oncology, 2021, 39, 1839-1841.	1.6	1
205	Response-adapted volume de-escalation (RAVD) of radiotherapy (RT) using induction chemotherapy (IC) in locally advanced head and neck squamous cell cancer (LA-HNSCC).. Journal of Clinical Oncology, 2015, 33, 6050-6050.	1.6	1
206	Characterization of potential predictive biomarkers of response to nivolumab in CheckMate-141 in patients with squamous cell carcinoma of the head and neck (SCCHN).. Journal of Clinical Oncology, 2017, 35, 5-5.	1.6	1
207	Tislelizumab (BGB-A317) + concurrent chemoradiotherapy (cCRT) followed by tislelizumab monotherapy for newly diagnosed locally advanced, unresectable, stage III non-small cell lung cancer (NSCLC) in a phase III study (RATIONALE 001).. Journal of Clinical Oncology, 2019, 37, TPS8574-TPS8574.	1.6	1
208	2022 Presidential Address: Advancing Equitable Cancer Care Through Innovation. Journal of Clinical Oncology, 2022, 40, 2859-2862.	1.6	1
209	Locally advanced non-small cell lung cancer. Current Treatment Options in Oncology, 2001, 2, 27-42.	3.0	0
210	Curative Treatment for Advanced Head and Neck Cancer in the Community. Cancer Journal (Sudbury,) Tj ETQqO 0 Q,rgBT /Overlock 10 T	2.8	0
211	Beyond PACIFIC: Uncharted Waters. Journal of Thoracic Oncology, 2021, 16, 715-718.	1.1	0
212	Alliance Foundation Trial 09: A Randomized, Multicenter, Phase 2 Trial Evaluating Two Sequences of Pembrolizumab and Standard Platinum-Based Chemotherapy in Patients With Metastatic NSCLC. JTO Clinical and Research Reports, 2021, 2, 100208.	1.1	0
213	Exploratory analysis of clinical and translational factors associated with the inflamed phenotype in HNSCC.. Journal of Clinical Oncology, 2015, 33, 3031-3031.	1.6	0
214	Comparison of two large, genetically and clinically annotated head and neck cancer (HNC) cohorts (TCGA, CHGC) and differential treatment effects on TP53 mutated, as well as oral cavity cancers.. Journal of Clinical Oncology, 2015, 33, 6080-6080.	1.6	0
215	Correlation of specific genetic aberrations and signaling pathways with T-cell inflamed phenotype (TCIP) in head and neck cancer and as novel candidate biomarkers for checkpoint blockade therapy.. Journal of Clinical Oncology, 2015, 33, 6079-6079.	1.6	0
216	Safety and resource use in the PROCLAIM study comparing 2 regimens of concurrent chemoradiation followed by consolidation chemotherapy in locally advanced nonsquamous non-small cell lung cancer (NSCLC).. Journal of Clinical Oncology, 2016, 34, 8529-8529.	1.6	0

#	ARTICLE	IF	CITATIONS
217	Immune subgroups and the tumor microenvironment as a potential new biomarker to assess response to immunotherapy. Chinese Clinical Oncology, 2019, 8, S24-S24.	1.2	0
218	Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Non-Small Cell Lung Cancer. Oncologist, 2001, 6, 25-27.	3.7	0
219	Docetaxel (Taxotere) in combination with radiation therapy and the potential of weekly administration in elderly and/or poor performance status patients with advanced non-small cell lung cancer. Seminars in Oncology, 2001, 28 Suppl 2, 22-27.	2.2	0
220	A Global Approach to Cancer Equity in the Hispanic/Latinx Population. JCO Oncology Practice, 2022, 18, 371-373.	2.9	0